'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial.

Amr S GamalHironori HaraMariusz TomaniakMattia LunardiChao GaoMasafumi OnoHideyuki KawashimaPeter JüniPascal VranckxStephan WindeckerChristian HammPhilippe Gabriel StegYoshinobu OnumaPatrick W Serruys
Published in: European heart journal. Acute cardiovascular care (2021)
Presentation with STEMI has not influenced the incidence of GLOBAL LEADERS defined primary endpoints. There were no significant differences in rates of NACE, POCE, and BARC bleeding between the two treatment groups up to 2 years of follow-up. Although these findings should be viewed as exploratory, they expand the evidence on potential safety of aspirin-free antiplatelet strategies after PCI in STEMI.